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Abstract: In this review we discuss recent progress in the
development, testing, and clinical evaluation of new
vaccines against tuberculosis (TB). Over the last 20 years,
tremendous progress has been made in TB vaccine
research and development: from a pipeline virtually
empty of new TB candidate vaccines in the early 1990s,
to an era in which a dozen novel TB vaccine candidates
have been and are being evaluated in human clinical
trials. In addition, innovative approaches are being
pursued to further improve existing vaccines, as well as
discover new ones. Thus, there is good reason for
optimism in the field of TB vaccines that it will be
possible to develop better vaccines than BCG, which is still
the only vaccine available against TB.
Introduction
It has proven challenging to develop vaccines against pathogens
whose control depends on the cellular immune response.
Tuberculosis (TB) is no exception. Most successful vaccines today
target pathogens against which humoral immunity suffices to
achieve protection and often sterile eradication. But TB vaccines
need to drive primarily the cellular arm of the immune system.
Mycobacterium tuberculosis (Mtb), the intracellular pathogen that
causes TB, was discovered in 1882 by Robert Koch (Nobel
Laureate in 1905) and is responsible for more human deaths than
any other single pathogen today [1–3]. The combination with
HIV co-infection, which dramatically compromises host resistance
to TB, leads to high disease prevalence in affected endemic
populations. Currently, each year more than 1.5 million people die
of TB, and more than 9 million newly develop TB [4]. This dire
situation is further compromised by the increasing prevalence of
multidrug-resistant (MDR) and extensively drug-resistant (XDR)
Mtb strains [5], and the more recent occurrence of TDR (totally
drug-resistant) Mtb strains, which are virtually untreatable [6].
TB, known also as the white plague, has been around for
millennia. Early last century, hopes were that TB could be
conquered by vaccination with the newly developed M. bovis BCG
vaccine, isolated by and named after Calmette and Gue ´rin in Lille,
France [7]. These hopes were further boosted by the development
of the first anti-tuberculous drugs during WWII by Selman
Waksman (Nobel Laureate in 1952), who discovered that
streptomycin was bacteriostatic for Mtb [8]. Initially, treatment
with streptomycin appeared highly efficacious, but the tide turned
when drug resistance rapidly developed, an early testimony of
Mtb’s ability to acquire drug resistance when treated by single
antibiotics. Despite this early writing on the wall, the misconcep-
tion that TB could be conquered by antibiotics and BCG
vaccination led to complacency for several decades. This situation
dramatically changed only in the early 1990s, when the World
Health Organization (WHO) declared TB a global emergency.
From that time onwards TB scientists, who had been focusing
much of their efforts on other areas of research and development
due to a lack of interest in and funding for TB, were able to
reorient efforts and initiate significant activities in the study of TB
[9]. Soon, researchers determined Mtb’s genome sequence [10],
and began to dissect TB’s immunology and cell biology.
Although in most cases, TB can be treated successfully with
multidrug combinations of antibiotics (except for MDR-, XDR-,
and TDR-TB), treating TB cases is clearly insufficient to interrupt
disease transmission in highly endemic populations, because an
active TB case will typically infect some 10 to 15 contacts [4] per
year. Better preventive measures that block Mtb transmission need
to be developed, including vaccines that prevent establishment of
Mtb infection in the susceptible human host (infection-blocking
vaccines), or alternatively, vaccines that prevent progression of
established infection towards active TB disease (disease-progres-
sion-blocking vaccines). The only available vaccine against TB
today remains the almost one-century-old BCG. It is routinely
administered to infants in many countries worldwide and provides
significant protection against severe forms of TB, mostly dissem-
inating and meningeal forms. However, the protective efficacy of
BCG against pulmonary TB in adults is inconsistent and
incomplete, and BCG vaccination campaigns have had little
impact on the occurrence of pulmonary TB, which represents the
transmissible form of this disease. It is still unclear why the
protective effect of neonatal or early-age BCG vaccination often
begins to wane in early adolescence, at least in TB-endemic areas,
as will be discussed further below. Nevertheless, in a North
American study, BCG’s protective efficacy was found to last for
over 50 years [11], thus pointing to the importance of possible
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genetics, TB exposure intensity, etc.; see below). Another issue of
concern that compromises BCG’s utility is that infants with HIV
have an increased risk of developing disseminated BCG-osis [12],
bearing similarities to individuals with genetic deficiencies in
the interleukin (IL)-12/IL-23/interferon-gamma (IFNc)/signal
transducer and activator of transcription (STAT)1 pathway
[13,14]. This implies that TB vaccines need to be developed that
not only have a superior ability to induce protective immunity
against TB, but also have a better safety profile compared to BCG
[12,15].
There has been significant progress in TB research over the
last 20 years. From a pipeline empty of new TB vaccine candidates
in the early 1990s, more than 12 novel TB vaccine candidates
now have been or are being evaluated in clinical trials in
humans. Moreover, many new approaches and strategies are
under evaluation for further improvement of these and other
vaccines. This raises hope that vaccines can be developed which
are better than BCG. It will be critical to mobilize the needed
funding, political, and supranational support, and increase
public awareness of the pressing needs in TB in order to step up
efforts towards controlling this resilient disease. The recent
declaration by the European Parliament to support TB vaccine
research and development (http://www.tbvi.eu/news-agenda/
news/news-message/eu-parlement-discusses-the-importance-of-tb-
vaccines.html) is a laudable step in this direction.
TB Infection Control
Infection with Mtb does not necessarily lead to TB disease. Only
3%–10% of immunocompetent individuals that are infected will
progress towards active disease during their life-time [16]. It is
unknown if—and what proportion of—infected individuals are
able to possibly achieve complete or ‘‘sterile’’ eradication of
bacteria following primary pulmonary infection. Existing yet
indirect evidence suggests that this may be the case and could be
dependent on innate rather than adaptive immune defense
mechanisms, as persons have been described who despite high
intensity exposure—and thus likely infection—remain tuberculin
skin test (TST)-negative and do not develop disease [17,18]. The
TST is a classical indicator of delayed type hypersensitivity-
dependent T-cell activity towards Mtb antigens in the case of
previous contact. TST surveys suggest that around one-third of the
world’s population, amounting for over 2.2 billion people, is
infected with Mtb [4]. Although .90% are able to contain
infection in a latent or subclinical stage, this huge reservoir of
latently infected individuals fuels the high numbers of new active
TB cases [19]. The development of active TB is dramatically
accelerated by co-infection with HIV, which increases Mtb
reactivation rates from 3%–10% per life-time to 5%–10% per
life-year [20]. Latent Mtb infection also poses iatrogenic clinical
challenges, due to increases in TB reactivation following admin-
istration of biologicals, such as tumor necrosis factor-alpha
(TNFa)/IL-12/IL-23 blockers in treating inflammatory diseases
like rheumatoid arthritis, Crohn’s disease, and psoriasis [21]. New
diagnostic tests that distinguish more specifically between Mtb
infection and BCG vaccination or infection with non-tuberculous
mycobacteria (NTM) than the classical TST have been developed
recently, based on Mtb antigen-specific release of IFNc in whole
blood or isolated leucocytes. These assays have been coined
interferon gamma release assays (IGRAs) and have utility in
clinical management, although sensitivity issues in borderline
IGRA-positive and in remotely infected persons, which may result
in false-negative test results, still need to be addressed [22].
A precise understanding of protective immunity and protective
host defense is still needed. The study of individuals who are able
to control Mtb infection in the long term may be particularly
informative in this respect. Despite two decades of intensified
research, we have to acknowledge that we still do not fully
understand what exactly constitutes protective immunity and host
defense against TB (see below section on TB immunology). If we
could decipher essential mechanisms, pathways, and biomarkers of
protection, then pathways of host defense could be targeted by
rationally designed vaccines, and protection measured by accurate
biomarkers [23,24]. Obviously, TB is much more complex than,
for example, many viral infections, in which highly pathogen-
specific mechanisms and correlates of protection exist in the form
of neutralizing antibodies. An additional challenge in TB is the
need to do better than achieve natural immune control of long-
term infection: notably, by inducing immune responses that not
only mediate life-long control of Mtb infection (which poses the
inherent risk of endogenous reactivation), but also achieve sterile
eradication of bacteria from the infected host. First-generation
new TB vaccines in clinical trials are designed to achieve stronger
immunity but may not necessarily succeed at sterile eradication
(discussed below) [25,26].
Besides mediating protection on its own, the host immune
response is also known to synergize with chemotherapy through
incompletely defined mechanisms [27]. Thus not only preventive,
but also therapeutic, TB vaccines that improve the host response
to chemotherapy will be of significance; the latter may help
shortening treatment, as well as reducing and perhaps treating
drug resistance.
M. bovis BCG: The Current TB Vaccine
BCG is the one of the most widely administered vaccines
worldwide, having been given over 4 billion times. BCG has been
part of the expanded program on immunization (EPI) since the
early 1970s and features relatively few serious adverse events. Only
fairly recently has it become apparent that individuals with genetic
defects in key immune genes or infants with clinically active HIV
infection are highly susceptible to developing disseminating BCG
disease, posing a significant risk in HIV-burdened populations
where TB is often highly endemic [12]. This has led to changes in
policy from the WHO Global Advisory Committee on Vaccine
Safety, recommending that BCG should not be used in HIV-
positive children.
Despite the relative efficacy of BCG in infants, the major
unanswered question is why BCG fails to prevent pulmonary TB in
adolescents. It has been proposed that immune memory wanes in
adolescence, which is the most critical period for TB infection and/
or its progression to active disease. The fact that immunological
memory is induced by BCG at an early age (neonates or infants) at
which the immune system is not yet fully mature may provide one
explanation. However, other factors may also contribute to
decreasing BCG efficacy and/or enhanced susceptibility of young
adults to TB. These factors include co-infections with helminths;
viruses that compromise host immunity (an obvious, extreme
example is HIV); and NTM that can induce immune regulation
[28]. Helminth infection has been associated with increased TB
incidenceand reduced BCGvaccine efficacy in affected populations
[29]. Such modulatory effects may be mediated by immune
deviation, e.g., the induction of T helper 2 (Th2) or regulatory T-
cell (Treg) responses, which dampen the protective efficacy of Th1-
dependent protection. A recent study in mice documented that
helminth infection can impair innate pulmonary host defense
against Mtb through the IL-4 receptor pathway [30].
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insufficient for worldwide TB control. Thus, there is a strong need
to develop vaccines that can either boost BCG’s initial priming
and protective effects, or replace BCG by superior vaccines. Both
strategies and approaches will be discussed below, after a short
introduction to the key immunological features of TB.
The Immunology of TB
Mtb organisms are transmitted by aerosols originating from the
lungs of persons with active TB. Mtb-loaded aerosols are inhaled
by TB contacts and reach the alveoli of their lungs, where they are
taken up by various cell types, including alveolar macrophages,
interstitial macrophages, local dendritic cells (DCs), and likely also
epithelial cells (Figure 1: Infection). In humans and mice, Mtb
infection is followed by a delayed onset of adaptive immune
responses when compared to other infections [31]. Recent studies
in mice have shown that Mtb possesses the unique ability to
establish infection while delaying the onset of an adaptive immune
response by 2–3 weeks. Using animals carrying genetically
engineered T-cell receptors specific for Mtb antigens, it has been
shown that priming of specific T-cell responses against Mtb takes
place only in the local draining lymph nodes of the lung, and that
transport of Mtb-infected cells from the lung parenchyma to the
lymph nodes is significantly delayed for a period of at least 1–2
weeks [32–36]. It remains unknown which cell types are involved
in Mtb antigen presentation to naı ¨ve T-cells, either DCs that cross-
present antigens from infected cells, or perhaps also DCs migrating
from the lung [37]. It is thought that Mtb can actively inhibit the
migration of infected cells from the lung to the draining lymph
nodes, or that Mtb can infect cells with only a poor migratory
potential like epithelial cells. In both cases, however, initiation of
Mtb-specific T-cell immunity is delayed. This ‘‘procrastination’’
strategy likely allows Mtb to establish infection and build up a
critical mass of infecting organisms, from which two types of
populations can be derived: (i) ‘‘dormant’’, ‘‘nonreplicating’’, or
persisting organisms that remain in a metabolic low activity state
in infected cells, and present a potential reservoir of bacteria that
can resuscitate later on in life (Figure 1: Latency); and (ii) actively
replicating metabolically active bacteria that stimulate the host
immune response, which confers protection but can also
precipitate TB pathology. The latter is hallmarked by the
formation of central caseous necrotic lesions, filled with extracel-
lular infectious Mtb and cell debris [38].
Mtb is able to persist inside otherwise hostile host cells, notably
professional phagocytes, by employing different immune evasion
strategies. These will not be discussed here in detail, but include
the inhibition of phagosome maturation, the inhibition of
autophagy, the inhibition of apoptosis, egression into the cytosol,
blocking of MHC antigen processing and presentation, and the
inhibition of IFNc-receptor signaling, all of which help Mtb to
evade host defence [39–43].
Following initial deposition of Mtb in the lung, macrophages
and other immune cells are recruited during the early innate
response to infection. The resulting cellular infiltrates become
organized as primary granulomas. These are highly dynamic
structures from which cells can rapidly in- and efflux. At a later
stage, when adaptive immunity has been initiated, specific T-
lymphocytes start infiltrating the granuloma; this leads to the
formation of larger, well-organized, solid granulomas in which Mtb
organisms typically are located mostly centrally. If control of
infection and inflammation is not balanced optimally, the central
regions of the granulomas will become necrotic and later caseous
as just discussed [44], allowing outgrowth of high numbers of Mtb
organisms. When these liquefying granulomas also damage airway
linings, infected material is discharged into the airways. At this
stage, TB infection has become contagious (Figure 1: Active TB
disease).
Thus immunity to Mtb is a two-edged sword: it protects the
human host against disseminating infection, but also facilitates
transmission of TB to contacts. Therefore, TB vaccines not only
need to induce optimal immunity to Mtb, but also a balanced
response that favors protective and avoids pathogenic mecha-
nisms.
The Mtb-specific immune response comprises a multitude of
different cell types. This ranges from classical and non-classical T-
cells to neutrophils, B-cells, and natural killer (NK) cells. The role
of CD4
+ Th1-cells in TB is best understood. Th1-cells, which
secrete IFNc and TNF as signature cytokines, are crucial for
protective immunity against mycobacterial infections. Their
induction is strictly dependent on the secretion of phagocyte-
produced IL-12 [13]. Deleterious mutations in genes encoding
proteins essential to the induction (IL-12p40 subunit, IL-12Rb1)
or function (IFNcR1, IFNcR2, Stat1) of Th1-cells, or their
depletion due to HIV infection, greatly enhance susceptibility to
severe infections due to otherwise poorly pathogenic mycobacteria
or Mtb [13,45]. This is also highlighted by the enhanced incidence
of TB reactivation during treatment with biologicals targeting
TNF, which are used in treating inflammatory disorders such as
rheumatoid arthritis, Crohn’s disease, and psoriasis [21].
CD4
+ Th1-cells recognize Mtb antigens presented by MHC-
class II molecules on DCs and macrophages [46–48], the
dominant habitats of Mtb. As mentioned above, CD4
+ T-cells
are initially primed in the draining lymph nodes of the infected
lung. Endosomal/phagosomal antigens like Mtb naturally access
the MHC-class II processing route, which leads to the presentation
of Mtb peptide-loaded MHC-class II complexes, providing ‘‘signal
1’’ at the DC surface. Only in the presence of a second signal,
which is provided by co-stimulatory molecules, such as CD80,
CD86, CD40, CD27, and 4-1BB/CD137, and a third signal,
provided by essential cytokines like IL-12, however, full activation
and differentiation of Th1-cells takes place. In the absence of any
of these three essential components, T-cell activation may either
not be initiated, or be preliminarily aborted; e.g., in the absence of
signal 2, T-cell tolerance/anergy can result. Recent studies suggest
that T-cell activation in TB granulomas is far from optimal but the
limiting factors, which may be antigen/MHC-class I/II availabil-
ity, lack of co-stimulation, or lack of supportive cytokines, still need
to be elucidated [49].
Next to CD4
+ Th1-cells, more recent evidence supports the
prominent activation of Th17-cells in TB. This is a recently
discovered T-cell subset that produces IL-17A, IL-17F, in many
cases IL-22 and TNF, and in some cases also IFNc. Th17-cells are
pro-inflammatory and mediate anti-microbial immunity against
extracellular bacteria and fungi, particularly at mucosal surfaces.
The exact mechanisms leading to Th17 activation and differen-
tiation are less clear than for Th1-cells but are believed to involve
phagocyte-dependent production of IL-1b or IL-6, and trans-
forming growth factor-beta (TGFb). Other studies have pointed
towards the essential role of IL-23, a closely related family member
of IL-12, in the induction and expansion of Th17-cells or Th17
memory cells [50]. Current evidence suggests that Th17-cells play
a significant role in the early phase of protection against high-dose
aerosol Mtb infection in mice [51,52]. Th17-cells emerged in the
early phase of adaptive immunity and contributed to host defense
against intracellular pathogens, including Mtb [53]: IL17A has
been found to be essential in forming mature granulomas in the
lung following BCG or virulent Mtb infection [54]. Their role
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of Th17-cells in previously Mtb-infected animals induced by
multiple BCG revaccinations was detrimental and led to increased
immunopathology with IL17-MIP2-dependent influx of neutro-
phils and tissue destruction rather than containment of infection in
the lung [55,56]. The major source of early IL-17 during infection,
however, may not be from CD4
+ Th17-cells but rather from T-cell
receptor gamma delta (cd) cells [54,56].
In addition to CD4
+ T-cells, CD8
+ T-cells also contribute to
optimal immunity and protection against TB [48,57]. The
mechanisms underlying CD8
+ T-cell activation in TB are
incompletely defined. It is clear that DCs possess multiple
pathways to load MHC-class I molecules, either by classical
cytosolic processing, or by alternative processing of phagosome-
located pathogens and endosome-located antigens. Active trans-
membrane transport, or leakage through micro-damaged mem-
branes of Mtb phagosomal antigens to the classical cytosolic
proteasome/MHC-class I presentation pathway, may also lead
to MHC-class I loading with Mtb peptides. The recent sugges-
tion that virulent mycobacteria can escape from the phagosome
into the cytoplasm and thereby directly access MHC-class I
processing/presentation may provide a new mechanism [43].
Thirdly, Mtb-infected cells can undergo apoptosis, leading to the
formation of apoptotic vesicles that are taken up by DCs, after
which the antigenic cargo is cross-presented through MHC-class I
and class II molecules [58,59]. Fourthly, autophagy, which plays a
prominent role in cellular homeostasis and in bacterial sequestra-
tion in vacuolar organelles, is involved in antigen presentation to,
and cross-priming of, T-cells in the response to intracellular
pathogens, including Mtb [60,61]. Thus, there are multiple
pathways for activation of CD8+T-cells by phagosomal antigens.
Besides classical MHC-class Ia-restricted CD8
+ T-cells, also
MHC-class Ib-restricted CD8
+ T-cells have received attention
recently [62,63] . These include HLA-E-restricted cells [64,65];
lung mucosal-associated invariant T-cells (MAIT) that recognize
Mtb antigens in the context of the non-classical molecule MR1
[66]; and CD1-restricted T-cells that mostly recognize lipid
antigens derived from Mtb. CD1b molecules follow the MHC-
class II presentation route, but relatively little is known for MR1
and HLA-E. HLA-E molecules are enriched in the Mtb
phagosome, thus providing a plausible mechanism for Mtb peptide
loading [66].
Figure 1. The three stages of tuberculosis. Stage 1: Infection of Mycobacterium tuberculosis (Mtb) frequently occurs at a young age.
Metabolically active Mtb are inhaled and subsequently T-cells are stimulated which carry the major burden of acquired immunity. These include major
histocompatability complex class II (MHC II)-restricted CD4 T-cells and MHC I-restricted CD8 T-cells. B cells are also activated but their protective role
in TB remains elusive. Pre-exposure vaccines are given at this early stage. Novel pre-exposure vaccine candidates are given very soon after birth and
thus generally before infection with Mtb. They either substitute for Bacille Calmette Gue ´rin (BCG) or boost immunity induced by BCG. Stage 2:
Acquired immunity comprising CD4 and CD8 T-cells contains Mtb in a dormant stage within solid granulomas. T-cells produce type I cytokines and
cytolytic effector molecules. They become memory T-cells which concomitantly produce multiple cytokines. Individuals remain latently infected
without clinical signs of active tuberculosis (TB). Post-exposure vaccines are given to adolescents or adults who are latently infected but healthy.
Stage 3: Mechanisms leading to deficient immunity and disease reactivation are numerous and include production of suppressive cytokines such as
interleukin (IL)-10 and transforming growth factor-beta (TGFb) by T helper 2 (Th2) cells and regulatory T(reg) cells as well as T-cell exhaustion
mediated by inhibitory receptor-coreceptor interactions on antigen presenting cells (APCs) and T-cells. Mtb becomes metabolically active and
granulomas become caseous. Mtb can be spread to other organs and to other individuals. Therapeutic vaccines are given to TB patients in adjunct to
chemotherapy.
doi:10.1371/journal.ppat.1002607.g001
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+ T-cells are endowed with multiple mechanisms to attack
Mtb-infected cells. Importantly—and in contrast to CD4
+ Th-
cells—CD8
+ T-cells are able to recognize non-phagocytic cells
such as epithelial cells, which can also be infected by Mtb [67].
All nucleated cells express MHC-class I molecules while only
professional phagocytes—or IFNc-activated cells—express MHC-
class II molecules and can be recognized by CD4
+ T-cells. Thus
CD8
+ T-cells are able to survey larger numbers of cells and a
broader range of cell types compared to CD4
+ T-cells. In addition,
as already mentioned above, CD8
+ T-cells are able to survey the
cytoplasmic compartment of infected cells for pathogen-derived
peptides through various antigen processing/presentation routes.
Thus CD8
+ T-cell immunity offers clear advantages and
complementarity to CD4
+ T-cell immunity.
CD8
+ T-cells are able to secrete granules that contain cytotoxic
molecules such as perforin, granzymes, and granulysin. These
molecules can lyse host cells, and in the case of granulysin, also
directly kill Mtb and other bacteria. In addition, CD8
+ T-cells can
induce apoptosis of infected target cells through ligating Fas or
other TNF-R family-related cell-death receptors. Apoptosis may
be activated to control Mtb infection (and is also counteracted by
virulent Mtb [68]. Thirdly, CD8
+ T-cells are also able to release
Th1 cytokines such as IFNc, TNF, and in many cases also IL-2.
These different effector pathways have been well documented in
humans [69–75]. These functions are also probably shared by
MHC-class Ib-restricted CD8
+ T-cells, suggesting a role in
protection for classical as well as non-classical CD8
+ T-cells in TB.
Besides T-cells, new evidence also suggests accessory roles for
NK-cells and B-cells in optimal immunity against TB [76].
Emerging evidence strongly suggests that the activation and
infiltration of granulocytes is associated with TB disease activity
and may play an important role in TB pathogenesis [77,78].
Recent genome-wide gene expression studies in TB patients
revealed a striking neutrophil-associated expression pattern that
was dominated by a type-1 interferon signaling signature. This
profile normalized after curative treatment of infection, and had a
core Mtb-specific component. Thus, other cells certainly contribute
to host defense in TB, and may provide new biomarker signatures
of pathogenesis, disease activity, and protective immunity.
Despite the more limited knowledge on the role of CD8
+ T-cells
in TB compared to CD4
+ T-cells, paradoxically there seems to
be greater consensus on ‘‘multifunctionality’’ as a marker of
protection in TB for CD8
+ T-cells than for CD4
+ T-cells. Multi-
or poly-functionality is a term used to describe the simultaneous
production of multiple cytokines (mostly IFNc, IL-2, TNF) or the
expression of multiple effector functions (perforin, granulysin,
cytolysis, etc.) by one single T-cell clone. For example, the co-
expression of IFNc and IL-2 by Mtb-specific CD8
+ T-cells was
associated with protective host defense following curative TB
treatment [70,79]. Conversely, there is some controversy whether
poly-functional CD4
+ T-cells are associated with protection, or
even with disease. Some reports, mostly derived from vaccination
studies in animals, have suggested that poly-functional (IFNc
+IL-
2
+TNF
+) CD4
+ T-cells are associated with protective immunity
[80,81], but more recent studies have suggested that these cells
may not indicate protection, and even mark TB disease activity
[82–84]. This issue clearly needs further investigation. In this
context, it needs to be realized that even during active TB disease
not all lesions in the human lung are reactivating. At least some
sites of infection are probably still controlled by the host immune
response. Thus, much akin to recent new models that describe
latent TB as a graded continuum of infection rather than as a
single static entity [85], it is likely that TB disease follows a similar
spectrum, ranging from the reactivation of only few lesions up to
full-blown activation of many lesions such as seen in rapidly
disseminating disease. It follows that in mild and less severe forms
of TB, in which only part of lesions is reactive, others may be
adequately controlled by the host response, which may involve
multi-functional CD4
+ T-cells. In any case, further studies to
resolve these controversies are eagerly awaited.
Besides T-cells endowed with protective effector functions, Mtb
also induces activation and expansion of regulatory T-cell (Treg)
populations. These range from naturally occurring, broadly
reactive CD4
+CD25
+FoxP3
+ Tregs, to antigen-specific-induced
CD4
+ Tregs [86,87] and newly identified CD8
+ Tregs, which have
been mostly identified in the human response to mycobacteria
[64,88,89]. These Treg have multiple inhibitory effects: they can
directly suppress CD4
+ Th-cell activity through secretion of IL-10,
CCL4, or the expression of membrane-bound TGFb; they can
deactivate APCs and thus inhibit optimal priming of CD4
+
responses; and they can inhibit the influx of CD4
+ T-cells into
draining lymph nodes, and/or inhibit their proliferation and
expansion [86], thus delaying and inhibiting onset of adaptive
immunity to Mtb.
Thus a multitude of interlinking cells and mechanisms are
involved in the immune response to Mtb infection, including
activating/effector, and inhibitory/regulatory functions. The
balance of the response and the ability to deliver effective hits to
Mtb-infected target cells dictates whether the host response will
lead to control of infection and possibly bacterial eradication, or
whether infection will progress with increasing numbers of
bacteria, lung tissue damage, and transmission of Mtb organisms
to new susceptible hosts [44].
Designing Better TB Vaccines: Two Basic and
Complementary Approaches
In the absence of reliable TB biomarkers of protection and a
human challenge model, TB vaccine design by necessity will have
to rely on empirical testing of candidate vaccines in long and costly
efficacy trials. The identification of protective biomarker signa-
tures would greatly facilitate vaccine discovery and testing [23,24].
If it were possible to identify a correlate with the same potency as
neutralizing antibodies against viruses, discovery of high profile
TB vaccine candidates and clinical testing could be markedly
accelerated. As of 2009, more than a dozen TB vaccine candidates
entered clinical trials, and many more are in the pre-clinical
pipeline to be considered for testing in phase I clinical trials [3].
Five vaccines are currently in phase I/IIa (safety/immunogenicity)
clinical trials and two of these are in larger phase II clinical trials.
At least 16 vaccine candidates are in advanced pre-clinical
development and well over 20 next-generation candidates are in
the discovery pipeline.
The development of new TB vaccines follows two basic avenues
[1,25,90]. The first aims at replacing BCG by either improved
recombinant (r)BCG or by genetically attenuated Mtb. The profile
of genetically improved rBCG should be: a) safer; b) more
immunogenic; c) inducing longer lasting protection; and d)
inducing protection against highly virulent clinical isolates such
as Mtb Beijing strains, as well as MDR, XDR, and TDR Mtb
strains. One way to improve BCG is either by introducing
immunodominant Mtb-specific antigens that are absent from
BCG, such as RD1 locus-encoded antigens (ESAT6, CFP10); or
by over-expressing antigens that BCG already expresses by itself
(cognates of Ag85 complex), but probably not sufficiently high
throughout all phases of infection. Another way to improve BCG
is by introducing genetic modifications for superior targeting of
essential immune pathways, for example, by enhancing or
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phagosomal maturation. Obviously, both strategies can be
combined [38]. Besides these two rBCG vaccine approaches, a
second major strategy to develop better live vaccines against TB
has been to attenuate Mtb. These strategies include the deletion of
essential metabolic genes to create auxotrophic mutants; or the
deletion of major virulence genes and their regulators (see below).
In either case, at least two independent genetic loci need to be
deleted to avoid reversion to virulence. One study engineered M.
microti to express RD1 Mtb antigens, which indeed resulted in better
experimental protection [91]. A recently published third type of live
mycobacterial vaccine against TB is recombinant M. smegmatis.
When a locus called esx-3 was removed from the M. smegmatis
genome, a strongly enhanced innate immune response was seen.
Unexpectedly, when this attenuated strain was complemented by
the transfer of the Mtb esx-3 locus, strong bactericidal and protective
activity against Mtb was observed in the mouse model, and in some
cases even leading to sterile eradication [92].
The second major avenue to develop better TB vaccines relies
on the development of subunit vaccines. These are non-live, or in
the case of viral vectors, non-replicating vaccines, which can be
delivered safely into the human host regardless of immunocom-
petence. Subunit vaccines in TB are mostly based on recombinant
proteins admixed with proper adjuvants, or the use of attenuated
viral vectors. Although subunit vaccines theoretically could be
used as priming vaccines, current views are that they may be
mostly used as booster vaccines on top of BCG-, recombinant
BCG-, or attenuated Mtb-priming vaccines. The subunit vaccines
are then anticipated to boost strong, long-lived immune responses
in already primed individuals, such that these will persist to levels
high enough to protect the 3%–10% vulnerable individuals against
TB disease.
The various types of vaccines and their intended use are
summarized in Table 1.
Live Vaccines, Aiming to Replace BCG as Priming
Vaccines
The first attempts to create improved BCG vaccines were made
by Horwitz et al., who over-expressed antigen 85B (Ag85B) in
BCG, called rBCG30 [93]. This vaccine resulted in improved
protection against TB in guinea pigs, and appeared to be
immunogenic in humans [94]. This vaccine has successfully
passed a phase I clinical safety trial but is currently on hold.
Following a similar strategy, selected RD1 antigens or larger parts
of the RD1 region were transferred into BCG [95]. The rBCG’s
profile indeed showed better immunogenicity, but this was
compromised by its enhanced virulence in SCID mice. Thus,
deleting the virulence determinants of this region may offer a
viable strategy to improve immunity while maintaining safety.
More recent studies engineered a recombinant BCG strain to
over-express Ag85A, Ag85B, and TB10.4 [96]. While appearing
to be safe and to induce high levels of IFNc-producing T-cells in
mice, its protective efficacy against TB was not improved
substantially over wild-type BCG.
Another approach to improve BCG has been the expression of
listeriolysin, while deleting expression of ureC in BCG [97].
Listeriolysin is derived from Listeria monocytogenes, the organism in
which it is required for phagosomal escape and translocation to the
cytosol of the infected cell. Listeriolysin likely perforates the
phagosomal membrane, allowing leakage of enzymes (such as
cathepsins and other proteases) and bacterial components into the
cytoplasm of the infected cell. Listeriolysin is only active at acidic
pH 5.5 and is degraded immediately in the cytosol because this
protein comprises a PEST sequence (i.e., a peptide sequence
containing the amino acids proline [P], glutamic acid [E], serine
[S], and threonine [T]), which induces its own degradation
[98,99]. Hence, its activity is restricted to the phagosome. These
features ensure safety of this construct. BCG normally expresses
UreC, which is able to counteract phagosomal acidification;
Table 1. Most advanced TB vaccine candidates in clinical trials.
Type Candidate Description Clinical Trial Status
Recombinant BCG for pre-exposure
prime vaccination
VPM 1002 rBCG-expressing listeriolysin and urease
deletion
Phase IIa ongoing
rBCG30 rBCG-expressing Ag85B Phase I completed/on hold
Aeras-422 rBCG-expressing perfringolysin and Ag85A,
85B, Rv3407
Phase I terminated due to side
effects
Viral-vector for pre-exposure booster
vaccination
Oxford MVA85A/Aeras-485 Modified vaccinia Ankara-expressing Ag85A Phase IIb ongoing
Crucell Ad35/Aeras-402 Replication-deficient adenovirus 35-expressing
Ag85A, Ag85B, TB10.4
Phase IIb ongoing
AdAg85A Replication-deficient adenovirus 5-expressing
Ag85A
Phase I
Fusion protein in adjuvant for
pre-exposure booster vaccination
Hybrid 1+IC31 Fusion of Ag85B and ESAT-6 in adjuvant IC31 Phase I, soon entering IIa
Hybrid 56+IC31 Fusion of Ag85B, ESAT-6 and Rv2660c in
adjuvant IC31
Phase I ongoing
Hybrid 1+CAF01 Fusion of Ag85B and ESAT-6 in adjuvant CAF01 Phase I ongoing
M72+AS01 or AS02 Fusion of Rv1196 and Rv0125 in adjuvant AS01
or ASO2
Phase IIa ongoing
Aeras-404: HyVac4+IC31 Fusion of Ag85B and TB10.4 in adjuvant IC31 Phase I
Whole bacterial vaccine for therapeutic
vaccination
RUTI Detoxified M. tuberculosis in liposomes Phase IIa ongoing
M. vaccae Inactivated M. vaccae Phase III completed
doi:10.1371/journal.ppat.1002607.t001
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acidic pH of the BCG phagosome facilitates the activity of
listeriolysin. The recombinant BCG lacking ureC and expressing
listeriolysin caused superior protection as compared to parental
BCG [97]. Interestingly, rBCGDUrec:Hly appeared to increase
apoptosis of infected host cells, and the resulting apoptotic vesicles
carrying vaccine components facilitated cross-priming by DCs,
inducing strong CD4
+ and CD8
+ T-cell responses. In addition, this
strain was found to activate Th17-cells, which next to the induced
Th1-cells, probably facilitated optimal immunity against Mtb
[59,100,101]. Importantly, this improved rBCG induced superior
protection not only against laboratory strains of Mtb, but also
against clinical Mtb isolates with high virulence, including Mtb
Beijing family strains. The rBCGDureC:hly vaccine VPM1002 has
now successfully passed a phase I clinical safety trial and has
entered a phase IIa trial in newborns in 2011 (Table 1).
Over-expression of perfringolysin in BCG had rather similar
effects as listeriolysin [96]. However, perfringolysin has a relatively
broad pH optimum and lacks the PEST sequence [38], such that it
can act from inside and outside the cell and remains active in the
cytosol. Indeed, a phase I clinical safety trial with rBCG-expressing
perfringolysin and Ag85A, Ag85B, as well as antigen Rv3407
(instead of TB10.4) [96,102], had to be terminated because of side
effects (reactivation of shingles [103]) (Aeras-422, see Table 1).
The second class of live Mtb vaccines comprises genetically
attenuated Mtb derivatives. Attenuation can be achieved by
inducing auxotrophy, or by deleting essential virulence genes.
Auxotrophy relies on deletion of genes involved in the metabolism
of essential nutrients for Mtb, such as amino acids or pantothenate.
The first auxotrophic Mtb strains were generated as early as
the mid-1990s [104]. More recently, promising candidates for
clinical evaluation have been generated, including the Mtb
DRD1DpanCD strain, which contains deletions in the major
Mtb RD1 virulence gene cluster as well as in the biosynthetic
pathway of pantothenate [105]. This strain induced efficient
protection in normal and immunocompromised mice, and featured
promising safety. Another promising attenuated Mtb derivative is
the DPhoPDfad Mtb strain [106]. The two-component transcrip-
tional regulator system PhoP/PhoR regulates the expression of a
large number of genes, including Mtb virulence genes. The highly
attenuated laboratory strain Mtb H37Ra was found to contain
an inactivating mutation in the phoP gene [107]. The fad gene
is involved in the synthesis of the cell wall lipid phthiocerol
dimycocerosate (PDIM). This vaccine candidate is aimed at
entering a phase I clinical safety trial in 2012.
Subunit Vaccines, Primarily Aiming to Boost
(Recombinant) BCG-Induced Responses
Subunit vaccines against TB are delivered either through viral
vector systems or as recombinant proteins mixed with adjuvants.
Two viral delivery systems for TB antigens are currently in clinical
trials: Modified vaccinia virus Ankara (MVA) expressing Ag85A
has proved extremely immunogenic in both naı ¨ve as well as BCG-
primed individuals, inducing high Ag85A-specific CD4
+ T-cell
responses in humans [108,109]. Replication-deficient adenoviral
systems have either used Ad5 or Ad35 platforms. Ad35 carrying
Mtb antigens Ag85A, Ag85B, and TB10.4 was highly immuno-
genic in humans, inducing strong CD4
+ and CD8
+ T-cell and
IFNc responses [110,111]. Both the MVA over-expressing Ag85A
and the Ad35 expressing Ag85A, Ag85B, and TB10.4 are
currently in phase IIb clinical trials. The interference of pre-
existing human antibodies that could neutralize and negatively
impact on adenoviral delivery needs further investigation, but may
not be a major impediment to at least some adenoviral vectors
[112]. New viral factors are currently being considered, such as
replication-defective lymphocytic choriomeningitis virus vectors,
which stimulate CD4
+ and CD8
+ T-cell as well as B-cell responses
[113].
Significant progress has been made in the construction and
testing of recombinant proteins, mostly fusion proteins that
combine two or more immunodominant antigens of Mtb. These
are invariably admixed with potent Th1-activating adjuvants. One
of the most advanced products is the Hybrid 1 fusion protein,
designed by Statens Serum Institute, which consists of Ag85B
fused to ESAT6. When administered together with the potent
IC31 adjuvant, which activates human Toll-like receptor (TLR)9
and facilitates antigen uptake by DCs, thereby providing a slow-
release depot [90], this product leads to strong CD4
+ Th1 IFNc
induction in humans. This was first reported in naı ¨ve human
volunteers [114]. An encouraging observation was the long-lasting
high-level immune response still detectable 2.5 years after the last
vaccination. More recently, the same vaccine was found to boost
immune responses previously induced by either BCG or latent Mtb
infection [115]. The Hybrid 1 fusion protein in IC31 adjuvant is
aimed at entering phase IIa trial in 2012. A very similar fusion
protein, Hyvac 4, which consists of Ag85B fused to the antigen
TB10.4 (which in contrast to ESAT6 is expressed also by BCG), is
in a parallel clinical development program (Table 1).
A similar approach was followed by GlaxoSmithKline (GSK)
that designed the M72 fusion protein, consisting of Mtb antigens
Rv1196 and Rv0125 [116]. The M72 fusion protein was admixed
with different GSK synthetic adjuvants and had a favorable
clinical profile in terms of safety and immunogenicity [116]. The
currently favored adjuvant is the AS01E, which contains mono-
phosphoryl lipid A, mixed with QS21; the first stimulates TLR4
and drives CD4
+ Th1 as well as Th17 responses, and the latter
primarily triggers CD8
+ T-cell responses. This vaccine is currently
undergoing phase IIa trial. Both AS01E and IC31 are liposomal
formulations. Currently other adjuvants are being constructed,
such as CAF01 [117,118]. This liposome-based formulation
combines dimethyldioctadecylammonium (DDA) with trehalose
6,69-dibehenate (TDB), a synthetic analogue of the mycobacterial
cord factor trehalose 6,69-dimycolate (TDM), which ligates the
innate immune receptor monocyte-inducible C-type lectin (Min-
cle) and has strong adjuvant properties [119].
Other antigens close to phase I clinical trial include heparin-
binding hemagglutinin (HBHA) [120]. HBHA is expressed by
both Mtb and BCG and is heavily methylated at its C-terminal
portion, against which T-cell responses seem to be specifically
directed [121]. The protein’s methylation is essential for tethering
to and invading human cells, including non-phagocytic cells [122];
this may relate to its ability to facilitate extrapulmonary
dissemination of infection. Besides HBHA many other antigens
have been discovered that could be interesting vaccine candidates.
These include TB latency antigens such as DosR regulon-encoded
proteins and starvation antigens like Rv2660, discussed below.
Designing Better TB Vaccines: The Next
Generation
New Antigens
Until now virtually all TB vaccine strategies have focused on
pre-exposure vaccination, which ideally induces strong, long-
lasting memory T-cell responses that are rapidly mobilized after
infection with Mtb and mediate protection. Recent work has
revealed that Mtb alters its metabolic state from active replication
to slow or non-replication during infection. This is accompanied
by significant changes in Mtb’s gene expression profile. The
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which antigens are available to the immune system as a result of
Mtb’s alterations in antigen expression when entering into
starvation or dormancy. Interestingly, this process is partly
immune pressure-dependent [123]. The expression of ‘‘early
secreted antigens’’ produced by replicating Mtb such as Ag85B
decrease whereas the expression of ‘‘latency antigens’’ is induced
or increased. Such Mtb latency antigens are, for example, encoded
by (i) the Mtb DosR regulon, which mediates Mtb’s response to
hypoxia; (ii) starvation antigens that are upregulated by Mtb upon
depletion of nutrients; and possibly also (iii) the broader enduring
hypoxic response (EHR) genes, which include many genes of the
DosR regulon [124–129].
Incorporation of starvation/latency antigens into further
improved (live or subunit) vaccines may enhance the impact of
these vaccines. The potential success of this approach was recently
reported by Peter Andersen and colleagues, who showed that
vaccination with a fusion protein linking the Hybrid 1 (Ag85B-
ESAT6) backbone to Mtb starvation/latency antigen Rv2660c
(termed Hybrid 56) induced superior protection against TB,
particularly against late chronic infection, when compared to BCG
or H1 vaccination. The Rv2660c gene had been selected because
of its strong upregulation under starvation conditions [130].
Indeed, this antigen was recognized by T-cells from immune
donors in a South African population [131]. H56 was also efficient
in preventing TB reactivation in a non-human primate model, in
which BCG priming was followed by fusion protein boosting. Even
when anti-TNF mAb was used in an attempt to trigger TB
reactivation, the vaccine-induced protection remained intact
[132]. This vaccine is entering phase I clinical safety testing in
2012.
It is also possible to consider alternative strategies, for example,
to include Mtb antigens that are expressed by early reactivating
bacilli, such as resuscitation-promoting factor antigens or down-
stream antigens [75,102,126]. The availability of a pool of
memory T-cells able to respond to these rapidly expressed
reactivation antigens might provide a means of promptly detecting
and controlling reactivated Mtb.
The Complex Milieu of the Vulnerable Human Host:
Immune Modulation by External, Environmental, and
Endogenous Factors
In real life, Mtb infection occurs in individuals who are often co-
infected by environmental microbes or pathogens that can
modulate immune responses, including responses to vaccination
such as BCG vaccination. Non-tuberculous (environmental)
mycobacteria (NTM) can significantly downregulate and alter
the profile of BCG-induced immune responses [15,133]. Nutri-
tional factors such as iron status and vitamin D, which influences
innate immunity by inducing anti-microbial peptides, such as
cathelicidin (LL-37) and autophagy in association with IFNc, also
impact TB host immunity [134,135]. Different Mtb lineages or
genetic differences in virulence between Mtb strains are also
important in this context. Clinical programs will need to compare
vaccination efficacy in different geographic and ethnic settings,
and evaluate the impact of differences in Mtb epidemiology and
strains or clades on vaccine-induced immune responses and
protective efficacy [1].
Mtb itself is a master regulator of immune regulatory circuits. It
induces strong CD4
+ and CD8
+ Treg activity that suppresses Th1
and Th17 responses (see above). Mtb exploits these regulatory
mechanisms, which are normally used to prevent excessive
inflammatory responses and accompanying tissue damage. In
addition, Mtb downregulates key pathways of protection such as
apoptosis, autophagy, and IFNc production as well as IFNcR
signaling. Of note, highly discriminative biomarkers upregulated
in T lymphocytes from TB patients as compared to latently
infected individuals comprise genes involved in inhibitory signaling
[136]. The likely synergistic effects of blocking multiple pathways
at multiple different levels, added to the delay in its transport from
the lung to the lymph node and the ensuing delay in priming T-
cell immunity, collectively create an environment in which Mtb
can establish a safe niche of infection from which it can seed the
human body with a new wave of bacteria whenever immune
pressure is alleviated, for example, during co-infection or
malnutrition. Thus, the challenge for new TB vaccines is not only
to induce strong memory immune responses with long-term
efficacy in ‘‘clean animal laboratory settings’’, but also to do so in
the face of the highly complex environmental, co-infection, and
immunoregulatory background of the vulnerable human host.
Therapeutic Vaccines
New TB vaccines should not only induce immune responses
that control existing or new infections at the latent stage, but
ideally also eradicate Mtb organisms from the human body and
achieve sterile eradication [25]. This would avoid the threat of TB
reactivation from latency that can occur decades after initial
infection. Such vaccines must also operate in the huge reservoir of
latently infected individuals. Vaccines considered to be useful in
such settings need to express antigens that are expressed by Mtb
organisms during latent-stage infection. A major unknown is the
precise mechanism that mediates protective immunity and
possibly sterile eradication of Mtb. Recent results obtained with
the above-discussed modified M. smegmatis vaccine are promising
[92] with respect to the latter. However, in the absence of detailed
knowledge, it would seem fortuitous to develop vaccines that
stimulate all arms of the immune system, including Th1 cells;
Th17 cells (that play a role in the early response, possibly through
the recruitment of neutrophils); CD8
+ T-cell populations with
cytolytic and tuberculocidal activity (e.g., through the activity of
perforin and granulysin; apoptosis; autophagy), as well as TCRcd
cells and NK T cells, which bridge innate and adaptive immunity,
and provide IL-17 and IFNc early in the response to infection
[137]; and perhaps, lipid reactive T-cells, notably CD1-restricted
T-cells that can express a myriad of relevant effector functions
against Mtb.
A Role for B-Cells and Fc Receptors?
Vaccines that prevent productive Mtb infection are needed.
Only very few bacilli are thought to reach the lung and establish
the primary complex. Theoretically, the availability of mucosal
antibodies at the site of infection could be valuable. It is interesting
to consider that recent studies have documented a hitherto
unappreciated role for B-cells in potentiating protective immunity
against Mtb [76]. What is the potential role of such antibodies?
First, they could target Mtb to macrophages for destruction, e.g.,
through FccR pathway activation. In this context it is interesting
to note that FccR is among the most discriminative markers
upregulated in latently infected individuals as compared to TB
patients [78,138]. Second, they might exert chemotactic functions
and attract additional immune cells such as monocytes, neutro-
phils, and NK cells to the site of infection. And third, by targeting
Mtb to Fc receptors, antibodies might promote activation and
antigen processing/presentation by DCs and macrophages and
promote microbicidal activity in these cells [139,140].
Other TB vaccination strategies should address the targeting of
the mucosal immune system. Much research is focusing on the
potential of mucosal immunity and its enhancement by local
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aerosol delivery of BCG or subunit vaccines in animal models was
highly effective in inducing rapid immunity at the site of infection
[141–144]. Exploring new routes of vaccination and targeting
unique mucosal immune response pathways, which include
mucosal cells such as intraepithelial cells, MAIT, and T-cells
expressing homing receptors for the lung, such as CXCR6 [145],
have been relatively unexplored in TB and may have high
potential. Even though such cells are unlikely to prevent TB
infection stricto sensu, their rapid early response is likely to
contribute to early control of infection, particularly because these
cells may respond to infection during a critical period in which Mtb
delays onset of adaptive immunity as discussed above.
Concluding Remarks
In striking contrast to only 10 years ago, the TB vaccine
candidate pipeline is now filled with a number of high-profile
candidates, some of which have already entered or are soon likely
to enter clinical trials. First immunogenicity profiles of vaccines
tested in humans look encouraging. Because we do not know the
mechanisms of protection against TB and are lacking surrogate
end-point biomarkers of protection, we cannot predict whether
these vaccines will have protective efficacy in humans. Neverthe-
less, many of these vaccine candidates have proven records in
animal models, ranging from mice to guinea pigs to non-human
primates, raising hopes they may also be protective in humans.
Vaccines may be used either as stand-alone vaccines or—more
likely—in heterologous prime-boost settings.
The next 10–15 years will be critical for TB vaccines to
demonstrate protective efficacy as well as safety. At the same time,
it must be realized that these first-generation vaccines are neither
designed to prevent infection nor to achieve sterile eradication, but
rather to better prime and/or boost infection control. Thus at best,
such vaccines will only inhibit or delay TB reactivation. Next-
generation vaccines should be designed aiming at preventing
infection or achieving sterile eradication, perhaps by redirecting
immune responses at Mtb antigens expressed during latency [124–
126,130] or by using new platforms [92]. The new vaccines,
especially subunit vaccines, most likely will need to be adminis-
tered multiple times in order to maintain adequate life-long
immune memory. Virtually nothing is known about the timing of
such boosting schedules when it comes to vaccines aimed at
inducing primarily cellular immunity. Finally, the impact of co-
infection, immune regulation, and environmental factors (nutri-
tion; type-2 diabetes) that enhance susceptibility to developing TB
disease remain ill-defined, and need further research.
In summary, there is reason for optimism in the field of TB
vaccines: there is a substantial portfolio of interesting TB vaccine
candidates in clinical phase-I/II testing, some of which are already
fairly advanced in the TB vaccine pipeline. This is complemented
by numerous promising candidates further upstream in the
pipeline. In fact, an emerging bottleneck may not be the number
of pre-clinical TB vaccine candidates that TB researchers can
produce, but rather the number of vaccines that can be tested
clinically in efficacy trials, given the limited clinical trial capacity
worldwide, i.e., a shortage that exists not only in Africa but also
in Asia [1,3]. Finally, the identification of TB surrogate end-point
biomarkers or ‘‘correlates of protection’’ may drastically reduce
the need for the current long-term large-scale clinical trials,
and thus will speed up TB vaccine discovery and clinical testing
[1,9].
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